普萘洛尔治疗婴幼儿肝脏血管瘤疗效初探

Treatment of Infantile Hepatic Haemangioma with Oral Propranolol

目的:观察口服普萘洛尔治疗婴幼儿肝脏血管瘤的疗效。方法:17例年龄15 d^11个月的多发性血管瘤患儿经彩色B超、CT、MRI检测诊断为肝脏血管瘤,其中女14例,男3例。所有患儿予以口服普萘洛尔治疗,每日维持剂量2 mg/kg,至少维持6个月,定期复诊,随访观察疗效。结果:17例患儿用药6个月后肝脏血管瘤均明显好转,B超提示结节较治疗前明显缩小,直径由2~44 mm缩小至0~20 mm,其中8例患儿皮肤血管瘤较治疗前明显缩小,颜色变浅。所有患儿用药过程中心电图、血压、血生化等检查均未出现明显异常,停药后病情均未出现反复。结论:普萘洛尔治疗婴幼儿肝脏血管瘤疗效确切且不良反应小,可作为一线治疗药物。

Objective： To observe the clinical effect of oral propranolol in the treatment of infantile hepatic haemangioma. Methods：Seventeen children with angiomatosis（14 females,3 males） were treated by oral propranolol after B-ultrasound and CT scan or MRI.The dose of propranolol was 2 mg /（ kg·d）,treatment was continued at least 6 months and the children were reevaluated monthly.Results： The hepatic hemangioma of seventeen cases were significantly improved after six months medication,ultrasound tip nodules was significantly reduced,the diameter from 2 - 44 mm down to 0 ~ 20 mm,of which 8 cases of children with skin hemangioma was significantly reduced,the color becomes shallow. There were no significant changes on ECG,blood pressure or blood biochemical during the treatment and no recurrents after drug withdrawal. Conclusions： Oral propranolol is a safe and effective treatment for infantile hepatic haemangioma. It may be used as a first line therapeutic modality.